<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051293</url>
  </required_header>
  <id_info>
    <org_study_id>097.HEP.2020.D</org_study_id>
    <nct_id>NCT05051293</nct_id>
  </id_info>
  <brief_title>Comparison of the Concentration of Estrogen and Testosterone Ratio in Male Patients With Cirrhosis and Hypotension</brief_title>
  <official_title>Comparison of the Concentration of Estrogen and Testosterone Ratio in Male Patients With Cirrhosis and Hypotension Compared to Male Cirrhosis Patients Without Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cirrhosis is an end stage in liver disease leading to replacement of normal liver tissue with&#xD;
      regenerative nodules surrounded by fibrous bands in response to chronic liver injury. It is&#xD;
      the eighth leading cause of death in the United States and the thirteenth leading cause of&#xD;
      death globally. Patients with cirrhosis have decreased spontaneous vascular resistance&#xD;
      leading to hypotension. The mechanism of hypotension in cirrhosis is thought to be a complex&#xD;
      result of the presence of increased level of circulating vasodilators such a nitric oxide&#xD;
      coupled with reduced resistance to vasoconstrictors and increased sensitivity to&#xD;
      vasodilators.&#xD;
&#xD;
      Another potential contributor to the development of hypotension in cirrhosis is thought to be&#xD;
      due to the increased production of estrogen in males especially the estrone (E1) and&#xD;
      estradiol (E2) concentration. The concentration of estrogen in cirrhotic patients is thought&#xD;
      to increase by fourfold compared to individuals without cirrhosis. The increased estrogen&#xD;
      concentration in cirrhosis patients results, in large part, from an increased peripheral&#xD;
      conversion from androgens including testosterone. Previous studies have shown that increased&#xD;
      estrogen concentration can cause a significant decrease in blood pressure in various cell,&#xD;
      animal, and human models. Of note, estrogen has also been shown to enhance nitric oxide&#xD;
      production in human beings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 22, 2021</start_date>
  <completion_date type="Anticipated">December 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 22, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum estrogen (E1 and E2) levels</measure>
    <time_frame>July to September 2021</time_frame>
    <description>Measurement of serum estrogen (E1 and E2) levels in cirrhotic males</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum testosterone levels</measure>
    <time_frame>July to September 2021</time_frame>
    <description>Measurement of serum testosterone levels in cirrhotic males</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Hypotension</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>male cirrhotic with hypotension</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>male cirrhotic without hypotension</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serum concentration of estrogen (E1 and E2) and testosterone ratio measurement</intervention_name>
    <description>To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients</description>
    <arm_group_label>male cirrhotic with hypotension</arm_group_label>
    <arm_group_label>male cirrhotic without hypotension</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male patients attending the outpatient clinic of the Liver Institute at Methodist Dallas&#xD;
        Medical Center, Dallas, Texas&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male cirrhotic patients &gt;18 years of age&#xD;
&#xD;
          -  Patient must attend the outpatient clinic of the Liver Institute at Methodist Dallas&#xD;
             Medical Center&#xD;
&#xD;
          -  willing to provide informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of cirrhosis &lt;18 years of age&#xD;
&#xD;
          -  Cirrhosis patients with active infection&#xD;
&#xD;
          -  Cirrhosis patients with active gastrointestinal bleeding&#xD;
&#xD;
          -  Cirrhosis patients on hormone replacement therapy testosterone&#xD;
&#xD;
          -  Cirrhosis patients on any antihypertensive medications&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Methodist Health System Clinical Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

